Vaxart, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $104.9M
- Price
- $0.432
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.98%
- Volume
- 354.9K
About
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Quick stats
Shares outstanding242.8M
Computed float235.3M
Float / shares96.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000072444
Websitehttps://vaxart.com
AI Summary
AI-generated1/25
minorneutralother
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Vaxart announced that a member of its management team will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, with Vaxart's slot on Monday, September 14 from 1:00 p.m. to 1:30 p.m. ET.
A live webcast will be available on the company's investor relations website, with a replay accessible for 30 days after the event; investors can arrange one-on-one meetings with management through their H.C. Wainwright representatives.
No new clinical, financial, or regulatory information was disclosed. Vaxart remains a clinical-stage biotech developing oral recombinant pill vaccines targeting coronavirus, norovirus, influenza, and HPV as its first immune-oncology indication.